The high prevalence of patients receiving PrPs or at risk of severe infections may also contribute for the significant proportion of parenteral APs observed in both hospitals, exceeding the 71.4% reported by a global study of 129 secondary care hospitals [17]. This evidence concerns the gene MSMB and infection.